CME Group (CME) general counsel sells 3,291 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

CME Group Inc. senior managing director and general counsel Jonathan L. Marcus reported an open-market sale of 3,291 shares of Class A common stock at $333.37 per share. After this transaction, he directly holds 7,192 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 18, 2025, indicating it was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 3,291 shares ($1,097,121)

Net Sell 1 txn

Insider Marcus Jonathan L

Role Sr MD General Counsel

Sold 3,291 shs ($1.10M)

Type	Security	Shares	Price	Value
Sale	Common Stock Class A	3,291	$333.37	$1.10M

Holdings After Transaction: Common Stock Class A — 7,192 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marcus Jonathan L

(Last) (First) (Middle)

20 SOUTH WACKER DRIVE

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr MD General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	03/17/2026		S		3,291(1)	D	$333.37	7,192	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 18, 2025.

Remarks:

	By: Margaret Austin Wright For: Jonathan L. Marcus	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CME (CME) report for Jonathan L. Marcus?

CME Group reported that senior managing director and general counsel Jonathan L. Marcus sold 3,291 shares of Class A common stock. The shares were sold in an open-market transaction at $333.37 per share, as disclosed in the Form 4 filing.

Was the CME (CME) insider sale by Jonathan L. Marcus pre-planned?

Yes, the sale was conducted under a Rule 10b5-1 trading plan adopted on February 18, 2025. Such plans pre-schedule trades, meaning the transaction timing was set in advance and not based on day-to-day market developments.

How many CME (CME) shares did Jonathan L. Marcus retain after the sale?

After selling 3,291 shares, Jonathan L. Marcus directly holds 7,192 shares of CME Group Class A common stock. This remaining position reflects his continuing equity stake in the company following the reported open-market transaction.

What price did Jonathan L. Marcus receive per CME (CME) share sold?

The reported transaction shows an average sale price of $333.37 per share for the 3,291 CME Group Class A shares sold. This price reflects the consideration received in the open-market sale disclosed in the Form 4.

What role does Jonathan L. Marcus hold at CME (CME)?

Jonathan L. Marcus is listed as Senior Managing Director and General Counsel of CME Group Inc. His Form 4 filing reflects insider activity by a key executive responsible for the company’s legal affairs and corporate governance matters.

Does the CME (CME) Form 4 show any option exercises or derivative trades?

No derivative transactions are listed in this Form 4. The filing shows only a single non-derivative transaction, which is the open-market sale of 3,291 shares of CME Group Class A common stock by Jonathan L. Marcus.